



LD Biopharma, Inc.
7384 Trade Street, Suite B
San Diego, CA 92121
Tel: 858-876-8266
<http://www.ldbiopharma.com>

- PRODUCT DATA SHEET -

Name of Product: Recombinant SARS-CoV-2 Nucleocapsid (N) Protein
Catalog Number: VRP-3105
Manufacturer: LD Biopharma, Inc. USA

Introduction

The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel Coronavirus: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Viral Nucleocapsid (N) protein (419aa) protein has been successfully used as immunogenic reagent for immunological / serological studies. This recombinant Nucleocapsid gene was codon optimized using gene synthesis technology, and was expressed in E. coli as inclusion bodies. The final product was refolded using our unique “temperature shift inclusion body refolding” technology and chromatographically purified.

Gene Symbol: Nucleocapsid (N)
Accession Number: MN908947
Species: SARS-Cov-2
Size: 50 µg / Vial
Composition: 1.0 mg/ml, sterile-filtered, in 50 mM HEPES Buffer: pH 7.5, with proprietary formulation of NaCl, KCl, Sucrose, DTT and others.
Storage: In Liquid. Keep at -20°C for long term storage. Product is stable at 4 °C for at least two weeks.

Key References

Wu, F. et al., 2020: *A new coronavirus associated with human respiratory disease in China.* Nature 579(7798): 265-269.

Ahmed, S. et al., 2020: *Targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV Immunological Studies.* Viruses, 12:254. doi:10.3390/v12030254

Wendong Li, et al., 2020: *Bats are natural reservoirs of SARA-Like coronaviruses,* Science. Vol : 310; 20 Oct. 676-678. (2005)




LD Biopharma, Inc.
 7384 Trade Street, Suite B
 San Diego, CA 92121
 Tel: 858-876-8266
<http://www.ldbiopharma.com>

Applications

1. Antigen for immunization as well as various immunochemical assays including ELISA and immunohistochemistry (IHC).

Quality Control

Purity: > 94% by SDS-PAGE.



Recombinant SARS-CoV-2 Nucleocapsid Protein (45.6 kD)

MSDNGPQNQRNAPRITFGGPSDSTGSNQNTERSARSKQRRPQGLPNNTASWFTALTQHGKEDL
 KFPRGQGVPIINTNSSPDDQIGYYRRATRIRGGDGKMKDLSPRWYFYLLGTGPEAGLPYGANKD
 GIIWVATEGALNTPKDHIGTRNPANNAIIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRN
 SSRNSTPGSSRGTSPTARMAGNNGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASK
 KPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTQDYKHWPQIAQFAPSASAFFGMSRI
 GMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKTFPPTPEPKDKKKKADETQALPQ
 RQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA